drugset / Trial / NCT00770003

Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

NCT00770003 ↗

Phase 1 Completed 103 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.

Timeline

Start
2008-09
Primary completion
2009-03
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8848 Small molecule 30 ug Intranasal
Subject AZD8848 Small molecule 60 ug Intranasal

Indications